Alibaba's Unprecedented $2.8bn Fine Could Signal Start Of Antitrust Wave In China
China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. Past cases show the pharma sector is not immune and while it remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions.
You may also be interested in...
While Alibaba and big tech giants are facing antitrust litigations in China, one pharma company finds itself land in hot water with a hefty fine.
China's latest national census data paint a mixed picture for the provision of health in the world’s most populous nation, with multiple major trends potentially impacting areas of opportunity.
Originated by a Suzhou-based biotech founded two years ago and now being jointly developed with WalVax, China’s first homegrown mRNA COVID-19 vaccine is now entering the final stages of development.